NewslettersIntestinal Cell NewsUncategorizedCombined MEK/MDM2 Inhibition Demonstrates Antitumor Efficacy in TP53 Wild-Type Thyroid and Colorectal Cancers with MAPK AlterationsBy Justin.choi - January 25, 2022029Researchers evaluated combination therapy with MEK inhibitor selumetinib and MDM2 inhibitor KRT-232 in TP53 wild-type and mitogen-activated protein kinase (MAPK) altered colon and thyroid cancer models.[Scientific Reports] 6445212 SPXSDFJC items 1 apa 0 default asc 1 171119 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/Full Article